thebench.bio #1 Ecosystem for the Bio-Tech Industry

Life Sciences Daily Summary

Life Sciences Daily Summary: What Happened on October 3, 2026

Novartis commits $575 million upfront for Abogen’s mRNA T-cell engager

Three deals for early Chinese programs carried large upfront payments. Foghorn and Lilly ended a cancer program, while three companies plan a Phase 3 combination trial.

  • Updated
  • Read from 6 articles, 4 publications
  • P B

Covers October 2 and October 3. There was no summary on October 2.

Today in brief

Novartis agreed to pay Abogen $575 million upfront for worldwide rights to ABO2203, an mRNA-encoded T-cell engager, and options on other programs.1 Abogen could receive up to $7.2 billion more if Novartis exercises every option and the programs meet milestones.1

Merck, Novo Nordisk and Novartis each agreed to pay at least $300 million upfront for early-stage Chinese assets, according to an October 2 analysis.2 Foghorn Therapeutics and Eli Lilly ended FHD-909 development after early results showed inadequate antitumor activity.3 AstraZeneca, Daiichi Sankyo and Summit Therapeutics plan a Phase 3 trial of a drug combination as initial treatment for triple-negative breast cancer.34

Novartis takes worldwide rights to Abogen’s mRNA engager

Novartis will pay Abogen $575 million upfront for exclusive worldwide rights to ABO2203 and options on other programs from Abogen’s RNA platform.15 Abogen could receive up to $7.2 billion in additional payments if Novartis exercises all options and the programs reach development, regulatory and commercial milestones. Abogen may also receive sales royalties.56

ABO2203 uses lipid nanoparticles to deliver mRNA, which instructs cells to make a protein linking CD3 on T cells with CD19 on B cells. This directs T cells to kill B cells.56 The drug is being studied in Phase 1 trials for autoimmune diseases and B-cell non-Hodgkin lymphoma.6 Preliminary results from nine people with lymphoma came from a small dose-escalation study in a different disease setting. They do not establish benefit in autoimmune disease.5

Large upfront payments are reaching earlier Chinese programs

Three agreements involving Merck, Novo Nordisk and Novartis each offered at least $300 million upfront for assets with little or no clinical data, an October 2 analysis found.2 Each deal had a potential total value above $2 billion and covered a different disease area and treatment type.2

The analysis said the agreements show China partnering extending beyond cancer antibody deals to programs without clinical proof of concept.2

Foghorn and Lilly end FHD-909 development

Foghorn Therapeutics and Eli Lilly stopped developing FHD-909 after Phase 1 dose-escalation results showed inadequate antitumor activity.3 The companies said tolerability and selective target engagement were acceptable. Foghorn CEO Adrian Gottschalk said the program did not show enough efficacy to continue.3

The partners had advanced the drug through a collaboration formed in 2021.3 Foghorn is cutting 40% of its workforce and shifting resources to four proprietary pipeline programs.3

Three companies plan a Phase 3 cancer-drug combination trial

AstraZeneca, Daiichi Sankyo and Summit Therapeutics plan a Phase 3 trial of Datroway with ivonescimab as initial treatment for triple-negative breast cancer.34 The companies also plan to study the combination in other tumor types, including lung cancers.34

The partners will supply their own medicines, AstraZeneca or Daiichi Sankyo will sponsor the trials, and all three companies will share costs while retaining rights to their drugs.4